Időskori makuladegeneráció: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration

  Eqon Pharmaceuticals, Llc· Carmel, Egyesült Államok· 233 247 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NEI · R01

  Metabolic tuning and signaling in retinal health and disease

  University of Wisconsin-Madison· Madison, Egyesült Államok· 608 985 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NEI · R21

  Leveraging Ocular B cells to identiry antigen triggers in uveitis

  University of Colorado Denver· Aurora, Egyesült Államok· 429 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NEI · U01

  RURAL Eye Health Study

  Southern California Eye Institute· Los Angeles, Egyesült Államok· 1 089 223 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NEI · R01

  Identifying barriers to retinal Muller glial reprogramming

  University of California, San Diego· La Jolla, Egyesült Államok· 499 606 USD awarded in fiscal year 2026· until 2030. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding retinal cell communication to counteract vision loss in aging (VisionGuard)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 263 393 EUR· until 2029. ápr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Drusen Reconstitution in an Engineered AMD Model using Retinal Pigment Epithelium (DREAM_RPE)

  Universidade Nova de Lisboa· Lisboa, Portugália· EU contribution 207 183 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Doctoral network on discovering pathomechanisms and novel drug optimization for AMD (PANDORA)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Németország· EU contribution 4 020 973 EUR· until 2030. szept.· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Full field optoretinography for elderly eye health (FFORGE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 150 000 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Lysophagy as a new strategy for neuroprotection in dry AMD (AMD_Prog)

  Universite de Fribourg· Fribourg, Svájc· EU contribution 307 959 EUR· until 2028. aug.

10 of 347 running projects, newest first. Listed amounts together: 182,7 M USD + 21,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 24

• AAV Gene Augmentation Therapy Rescues the Phenotype in the RDH5-/- Cat Model of Fundus Albipunctatus.

  Invest Ophthalmol Vis Sci, 2026. okt.

• Development of a Targeted Choroidal Injury Model for the Study of Retinal Degenerations and Therapeutic Cell Replacement.

  Transl Vis Sci Technol, 2026. aug.

• From Subretinal to Intraretinal Fluid in Type 1 Macular Neovascularization: A Clinicopathologic Disease Transition Model.

  Invest Ophthalmol Vis Sci, 2026. aug.

• Functional and Structural Characterization of a Large Animal Model of RDH5-Associated Retinopathy.

  Transl Vis Sci Technol, 2026. aug.

• RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

  Invest Ophthalmol Vis Sci, 2026. máj.

• Müller Cell Changes and Subretinal Membrane Formation in an Eye With Multifocal Geographic Atrophy.

  Invest Ophthalmol Vis Sci, 2026. ápr.

• Choroidal Vascular Findings in a Case of Multifocal Geographic Atrophy: A Clinicopathologic Correlation.

  Invest Ophthalmol Vis Sci, 2026. márc.

• The effects of zinc supplementation on primary human retinal pigment epithelium.

  J Trace Elem Med Biol, 2018. márc.

• Cone Viability Is Affected by Disruption of Melatonin Receptors Signaling.

  Invest Ophthalmol Vis Sci, 2016. jan.

• Bis(zinc-dipicolylamine), Zn-DPA, a new marker for apoptosis.

  Invest Ophthalmol Vis Sci, 2014. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.